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4 isolated muscle mitochondria from transgenic mice overexpressing human UCP3 may well be an artefact of protein abundance in the inner membrane, rather than a subtly regulated proton leak through UCP3 (Cadenas et al., 2002) . Data from UCP3 knock-out mice have yielded ambiguous results, in that the absence of UCP3 has been shown to have no effect on state 4 oxygen consumption (Vidal-Puig et al., 2000; Cadenas et al., 2002) or proton leak (Cadenas et al., 2002) in some studies, while having an effect on state 4 oxygen consumption (Gong et al., 2000) or proton leak (Vidal-Puig et al., 2000) in others. Other data where UCP2/3 was over-expressed in cells suggests that UCP3 (and UCP2) are associated with calcium transport across the mitochondrial inner membrane (Trenker et al., 2007; Trenker et al., 2008) , although these data are strenuously contested (Brookes et al., 2008) . Lombardi et al. (2010) have recently provided evidence that UCP3 translocates in vitro generated lipid hydroperoxides from the matrix of isolated mitochondria, with the net manifestation of uncoupling.
The observation that physiological modulation of UCP3 abundance through starvation, which is known to increase UCP3 protein expression and abundance in mitochondria (2-3-fold increase per mg mitochondrial protein) but does not manifest itself as increased proton leak in isolated skeletal muscle mitochondria from starved animals (Cadenas et al., 1999) suggests that if UCP3 facilitates proton leak it needs to be activated in vivo to perform that function. Certainly, others have shown that UCP3 can act to facilitate a purine-sensitive proton leak, on addition of superoxide (Echtay et al., 2002) or polyunsaturated fatty acid oxidation products (such as 4-hydroxy-2-nonenals) to isolated mitochondria (Echtay et al., 2003) , although the specificity of this activation by fatty acid oxidation products has been questioned by Shabalina et al. (2006) . A most fascinating piece of evidence for the in vivo activation of
5 put forward for the activation process stems from the fact that, apart from its central psychotropic effect, MDMA is known to trigger the sympathetic nervous system. Thus the activation of UCP3 in skeletal muscle on administration of MDMA to animals may result via release and binding of free fatty acids to UCP3 (Mills et al., 2004; Mills et al., 2007) , in an analogous way to activation of UCP1 by free fatty acids in brown adipose tissue following release of noradrenalin under conditions of cold-acclimation (Nicholls and Locke, 1984; Cannon and Nedergaard, 2004; Shabilina et al., 2004; Nicholls, 2006) .
However, in light of the observation from our laboratory that phosphorylation of UCP1 is augmented under conditions of cold-acclimation (Carroll et al., 2008) , we set out to investigate whether in vivo phosphorylation of UCP3 was the means by which UCP3 was activated to increase proton leak following MDMA administration.
Material and methods

Animals
Wistar rats were 8-12 weeks old, a mix of male and females and weighed between 150-200g. Mice were of C57 x 129 F2 background and either UCP3 -/-(homozygotes) or wild-type (+/+) for UCP3, originally from the Jackson laboratories. Mice were males aged between 6-10weeks weighing approximately 30g. Animals were housed at 25±1°C in individually ventilated cages. All animals were allowed free access to food [Harlan 2018 Teklad Global 18% Protein Rodent diet] and water and a 12-hour light/dark cycle was in place. All mice were killed by cervical dislocation and rats by CO 2 asphyxiation. All animals were housed in the Bioresources unit, in Trinity College Dublin.
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Synthesis of 3,4-methylenedioxymethamphetamine (MDMA)
MDMA was synthesized in a three-step reaction via reductive amination of the 1-(3,4-methylenedioxyphenyl)-2-propanone (PMK) precursor with modifications to the previously reported procedure by Gimeno et al. (2005) . 1-(3,4-methylenedioxyphenyl)-1-nitropropene was obtained from a
Henry-Knoevenagel condensation of 3,4-methylenedioxybenzaldehyde and nitromethane, using either potassium fluoride and N,N-dimethylamine hydrochloride or cyclohexylamine as organic base. The nitrostyrene was then reduced with iron powder in glacial acetic acid to afford PMK. Reductive amination of the ketone with NaCNBH 4 and methylamine afforded the MDMA product, which was used as the hydrochloride salt of MDMA in this study (see supplement to Experimental Procedures).
Synthesis of 1-(3,4-Methylenedioxyphenyl)-2-nitro-1-propene
To a solution of piperonal (10.0 mmol, 2.07 g) in glacial acetic acid (15 ml; Method A) or toluene (15 mL; Method B) was added nitroethane (20.0 mmol) followed by potassium fluoride (1.5 mmol, 87 mg) and N,N-dimethylamine hydrochloride (20.0 mmol, 1.63g) (Method A) or cyclohexylamine (10.00 mmol, 0.99 g), (Method B). The reaction was heated in a water bath for 6 h, water (50 mL) was added and the reaction mixture was allowed to stand overnight. The precipitated nitroethene was isolated by filtration.
The filtrate was further diluted with water (50 mL) and extracted with dichloromethane (3 x 25 mL). The organic phases were combined and washed with satd. aq. NaHCO 3 (3 x 25 mL). The solution was dried over anhydrous Na 2 SO 4 , filtered and all solvent removed in vacuo, to give an oil which was purified by column chromatography over silica gel (eluent: 7:3 hexane/diethyl ether). 
Synthesis of 1-(3,4-Methylenedioxyphenyl)-2-propanone -
A suspension of iron powder (10 mmol, 0.55 g) in glacial acetic acid (30 mL) was heated on a steam bath for 20 mins, stirring occasionally. To this mixture, a solution of 1-(3,4-methylenedioxyphenyl)-2-nitro-1-propene (2.2 mmol, 0.45 g) in glacial acetic acid (20 mL) was added over 20 min. The reaction was heated for 2.5 h until the mixture became a grey/white colour. The reaction was cooled and poured into a mixture of water/ice (100 mL). The product was extracted with dichloromethane (4 x 25 mL) and the organic extracts were washed with 15 % aq. NaOH (3 x 25 mL). The organic phase was then dried over anhydrous Na 2 SO 4 and concentrated in vacuo, to afford the product, which required no further purification. Colourless oil (50 %). (Dal Carson, 1990 28.70, 50.09, 100.60, 108.02, 109.30, 122.06, 127.34, 146.23, 147.38, 206.15 . HRMS (EI) calculated for C 10 H 10 O 3 Na: (M + + Na) 201.0519: found 201.0528.
Synthesis of 2-N-methylamino-1-(3,4-methylenedioxyphenyl)propane (MDMA)
To a solution of 1-(3,4-methylenedioxyphenyl)-2-propanone (10 mmol, 1.78 g) in dry methanol (30 mL) was added methylamine HCl (80 mmol, 5.40 g) and NaCNBH 4 (14 mmol, 0.52 g). The mixture was stirred at room temperature for 72 h and monitored by TLC. The pH was adjusted occasionally to pH 5-6 using 4M methanolic HCl. When the reaction was complete, excess hydride was quenched using 10 % aq. HCl (30 mL). The aqueous solution was washed with dichloromethane (3 x 25 mL). The aqueous phase was basified with 2M NaOH and extracted with dichloromethane (3 x 25 mL). The organic A
Isolation of mitochondria from liver
Mitochondria were isolated by differential centrifugation essentially as described by Chappell and Hansford (1972) . Liver was removed weighed and placed in an ice-cold sucrose based buffer (250mM sucrose, 5mM tris-HCl pH 7.4, 2mM ethylene glycol-bis(β-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA)). The liver was chopped finely using a scissors and washed several times with the aforementioned sucrose based buffer. The chopped liver was homogenized by hand using a Dounce homogenizer and the homogenate was subjected to centrifugation at 800xg for 3min at 4 0 C. The resulting supernatant was subjected to centrifugation at 12,000xg for 10min at 4 0 C yielding a pellet of mitochondria. The pellet was washed by resuspension in sucrose based medium and subjected to centrifugation under the same conditions. The resulting "mitochondrial" pellet was resuspended to the required concentration and stored on ice. Liver mitochondria from MDMA treated and PBS treated animals were prepared in the presence or absence of phosphatase inhibitors (10mM KF and 1mM Na 2 VO 3 ).
Isolation of skeletal muscle mitochondria
Skeletal muscle mitochondria from the hind leg muscle of rats or mice were isolated by the method described by Bhattacharya et al. (1991) . Hindquarter muscle (leg muscle) were removed weighed and placed in ice cold isolation medium (100mM sucrose, 9mM ethylenediamineacetic acid (EDTA), 100mM
tris-HCl pH 7.4, 46mM KCl). Skeletal muscle was finely chopped on a pre-cooled glass tile with a razor blade, transferred to isolation medium containing 0.02% (w/v) bovine serum albumin (BSA) and 0.02% (w/v) nagarse (Sigma, protease VII) and incubated on ice with stirring, for 5min.The tissue was further disrupted using a Waring blender at half-maximum speed for 15sec. The homogenate was subjected to centrifugation at 1,500xg for 3min at 4 0 C. The whitish lipid layer on top of the supernatant was removed A C C E P T E D M A N U S C R I P T
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10 and the supernatant was subjected to centrifugation at 12,000xg for 10min at 4 0 C. The resulting mitochondrial pellet was re-suspended in ice cold isolation medium containing 2% (w/v) essentially fatty acid free BSA and centrifuged at 12,000xg for 10min at 4 0 C. The resulting mitochondrial pellet was resuspended in ice cold isolation medium and subjected to centrifugation at 12,000xg for 10min at 4 0 C and the resulting pellet re-suspended in ice cold isolation medium to the required concentration.
Skeletal muscle mitochondria from MDMA treated and PBS treated animals were prepared in the presence or absence of phosphatase inhibitors (10mM KF and 1mM Na 2 VO 3 ).
Mitochondrial Protein Determination using the Bicinchoninic Acid Assay (BCA)
Quantification of protein concentrations in tissue samples was carried out using the bicinchoninic acid (BCA) assay described by Smith et al .(1985) . All of the following solutions (standards or samples) were directly prepared in a 96-well plate. A standard protein solution of BSA was suitably diluted in deionized water from 0 to 0.25mg/ml. The amount of mitochondrial protein present in the samples was determined by reference to a standard curve derived from the above known concentrations of BSA. was measured spectrophotometrically at 550nm.
Polyacrylamide electrophoresis
Samples were prepared as described in Cunningham et al. (2003) . Essentially (10-100μg) protein were solubilized in sample buffer, vortexed and pulsed in a minifuge before boiling at 100 0 C for 5min.
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mitochondrial samples were run on linear one-dimensional SDS (12%) polyacrylamide denaturing gels under reducing conditions using a Protean III (Bio-Rad) gel system.
Immunoblotting
Protein was transferred to polyvinylidene difluoride (PVDF) (Immobilin-P SQ ; Millipore) using a semi-dry apparatus for 2h at 110mA or a Bio-Rad Transfer Cell for 1-4h at 20V/cm. After transfer was complete, the PVDF was washed three times for 10min in phosphate-buffered saline ( Blots were developed using an ECL detection system (Amersham Biosciences), and immunoreactions were visualized by exposure to Kodak X-Omat LS film.
Immunoprecipitation
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either ( was eluted by heating beads in 2x sample buffer for 5 minutes at 95°C and the samples were subjected to SDS-PAGE (12% resolving gel) and immunoblot analysis. UCP3 was detected using a 1:1,000 dilution of affinity purified anti-UCP 3 peptide antibody (custom made by Eurogentec).
Measurement of Oxygen Consumption by Mitochondria
All measurements of respiration were made using an Oxygraph-2k respirometer (Oroboros Instruments, Innsbrück, Austria), and oxygen flux was resolved using DATLAB software. The oxygraph2k is a two chamber titration-injection respirometer with a limit of oxygen flux detection of 1pmol s -1 ml -1 .
Standardized instrumental and chemical calibrations were performed to correct for back diffusion of oxygen into the chamber from the various components; leak from the exterior, oxygen consumption by the chemical medium, and sensor oxygen consumption. The mitochondrial suspension was stirred using a PVDF magnetic stirrer and thermostatically maintained at 37°C. Oxygen consumption rates by mitochondria (0.0625mg/ml) were determined at 37°C in 120 mM KCl, 5 mM Hepes-KOH (pH 7.4), 1mM EGTA, 1 μM atractyloside, 1 μg/ml oligomycin, 0.1% de-fatted BSA, 1 µM rotenone and 5 mM succinate-KOH in a pre-calibrated Oroboros Oxygraph. Steady-state non-phosphorylating oxygen consumption rates due to proton leak were obtained (state 4), before subsequent addition of 1 mM
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GDP followed by the addition of 60 µM (~25nM estimated final concentration based González-Barroso et al., 1998) oleate and 0.25 µM FCCP, to obtain the uncoupled (maximal electron transport chain) rate.
Statistics
All data are expressed as means ± S.E.M. of at least 3 separate experiments performed in triplicate.
Statistical differences were determined by a two-tail unpaired student's t-test. Unless otherwise stated a p value of ≤ 0.05 was taken to indicate significance. Figure 1A demonstrates the selectivity and sensitivity of the UCP3 peptide antibody. The UCP3
Results
Selectivity of the detection of UCP3
antibody detects UCP3 expressed in yeast lysates of yeast overexpressing UCP3 (Cunningham et al., 2003) and mitochondria isolated from skeletal muscle from wild-type mice, but not in mitochondria isolated from skeletal of UCP3 knock-out mice or in liver of wild-type mice (where there is no UCP3 present). The presence of mitochondria was confirmed using an antibody to pyruvate dehydrogenase subunit E1α (Fig. 1B) . These data are consistent with selectivity and sensitivity determinations using this antibody previously reported by Cunningham et al. (2003) . From these data we can conclude that the UCP3 antibody is selective for UCP3.
UCP3 detection following MDMA and PBS treatment
Injection of animals with either MDMA or PBS, 2hours before sacrifice, had no effect on the protein expression levels of UCP3 in muscle isolated from animals in the presence or absence of phosphatase inhibitors ( Fig. 2A) . Confirmation of the presence of mitochondria in the preparations was demonstrated using an antibody to pyruvate dehydrogenase subunit E1α (Fig. 2B ). From these data we conclude that levels of UCP3 protein expression are not affected by MDMA or PBS injection or isolation of skeletal muscle mitochondria in the presence or absence of phosphatase inhibitors.
3.3 Detection of phosphorylated mitochondrial proteins following MDMA and PBS treatment Figure 3 demonstrates that many proteins in muscle mitochondria are either phosphorylated on tyrosine or serine. Clearly administration of MDMA increases the detectable levels of mitochondrial protein that are tyrosine phosphorylated compared to mitochondria isolated from animals treated with PBS alone ( Figure 3A ). The differential is less obvious for proteins that are serine phosphorylated in a comparison of skeletal muscle mitochondria from MDMA and PBS treated animals ( Figure 3B ).
Furthermore, and as might be expected, one can preserve a greater level of mitochondrial protein phosphorylation (serine and tyrosine phosphorylation) when the phosphatase inhibitors (10mM KF and 1mM Na 2 VO 3 ) are included in the mitochondria preparation medium. A similar pattern of mitochondrial protein phosphoryaltion to that of phosphoserine, was observed for phosphothreonine (results not shown).
We conclude that MDMA administration to animals causes a greater degree of phosphorylation of mitochondrial proteins (particularly evident for phosphotyrosine) then when animals are treated with PBS alone. We further conclude that addition of the phosphatase inhibitors (10mM KF and 1mM Na 2
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15 VO 3 ) to the mitochondrial preparation medium increases chances of preserving the phosphorylation state of mitochondria on isolation. , 5B, 5C and 5D). Similar results were obtained for skeletal muscle mitochondria and liver mitochondria from mice (data not shown). We conclude that state 4 oxygen consumption rate by skeletal muscle mitochondria is only increased in MDMA treated animals and the increase is preserved by the presence of phosphatase inhibitors in the preparation medium.
Immunoblots detecting phosphorylated UCP3 following MDMA treatment
Increase in state 4 oxygen consumption (proton leak) of skeletal muscle mitochondria from MDMA treated animals is due to phosphorylated UCP3
In order to determine whether the increased state 4 oxygen consumption rate by skeletal muscle mitochondria from MDMA treated animals compared to PBS treated animals, isolated in the presence of phosphatase inhibitors, was due to UCP3 phosphorylation, we compared state 4 oxygen consumption rates in skeletal muscle mitochondria from wild-type and UCP3 knock-out mice. Our data show that the state 4 oxygen consumption rate, with succinate as substrate, were significantly greater only in skeletal muscle mitochondria isolated from wild-type mice compared to UCP3 knock-out mice in animals treated with MDMA plus phosphatase inhibitors (MDMA treated wild-types 82.0±2.3; MDMA treated UCP3 knock-outs treated 64.0±1.5; p=0.003; n=3). Units are nmol dioxygen/min/mg mitochondrial protein) ( Figure 6A ). There was no difference in the state 4 oxygen consumption rate with succinate as substrate in skeletal muscle mitochondria, isolated from wild-type mice when compared to UCP3 knock-out mice, from MDMA treated animals prepared in the absence of phosphatase inhibitors ( Figure 6B ), nor was there significant difference in state 4 oxygen consumption rate in a comparison of mitochondria from UCP3-/-mice isolated in the presence of phosphatase inhibitors ( Figure 6A ) with
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18 mitochondria from wild-type or UCP3-/-mice isolated in the absence of phosphatase inhibitors ( Figure   6B ). Furthermore, there was no difference in state 4 oxygen consumption rates of liver mitochondria, respiring on succinate, isolated from isolated from wild-type mice when compared to UCP3 knock-out mice, from MDMA treated animals prepared in the presence of phosphatase inhibitors ( Figure 6C ).
Consistent with the data for succinate as substrate, our data show that the state 4 oxygen consumption rate, with glycerol-3-phosphate as substrate, was significantly greater in skeletal muscle mitochondria isolated from wild-type mice when compared to UCP3 knock-out mice in animals treated with MDMA plus phosphatase inhibitors ( Figure 6D Gong et al. (2000) . We conclude that the increase in state
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Discussion
We have provided evidence that MDMA treatment of animals causes in vivo phosphorylation of UCP3 in skeletal muscle mitochondria, the consequence of which is activation of UCP3, to increase proton leak in skeletal muscle mitochondria.
Confidence in antibody specificity is crucially important and we have demonstrated that the UCP3 peptide antibody we are using is in this study is selective for UCP3 over other mitochondrial transporters (Figure 1 ). These data are consistent with previously reported selectivity determinations for this antibody over other mitochondrial transporters including UCP1 and UCP2 (Cunningham et al., 2003) and its use for detection of UCP3, in mitochondria from thymocytes and splenocytes (Carroll et al., 2004) . The usefulness of the antibody is also reflected in its sensitivity to detect UCP3 cleanly in whole muscle homogenates (Cunningham et al., 2003) .
Using this antibody, we show that the amount of UCP3 protein present in skeletal muscle mitochondria is not affected 2 hours after treatment of animals with MDMA ( Figure 2 ). These data are not too surprising as one might not expect to see a significant change in UCP3 protein abundance within 2 hours after MDMA treatment. Furthermore, as expected, UCP3 abundance is not affected by addition of phosphatase inhibitors to the mitochondrial preparation, and clearly the phosphatase inhibitors are not affecting the ability to detect UCP3.
The data in Figure 3 demonstrate that MDMA administration to animals causes a greater degree of phosphorylation of mitochondrial proteins then when animals are treated with PBS alone, particularly evident for phosphotyrosine. Furthermore, the addition of the phosphatase inhibitors to the
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20 mitochondrial preparation medium, increases the capacity to preserve the in vivo sites of phosphorylation of mitochondrial proteins once mitochondria are isolated.
The phosphorylation protection protocol was inspired by Lee et al. (2009) who demonstrated preservation of labile phosphorylation within cytochrome oxidase, when phosphatase inhibitors were incorporated in to the preparation medium of heart mitochondria with the subsequent demonstration that cytochrome oxidase activity can be regulated by tyrosine phosphorylation of subunit IV.
Our data go on to show that skeletal muscle mitochondrial UCP3 is one of those proteins UCP3, yet a lack of detection of phosphorylation of threonine in UCP3, may reflect a degree selective activation of UCP3. Future endeavours will identify the phosphorylation sites within UCP3.
In order to discover whether in vivo mitochondrial UCP3 phosphorylation affected mitochondrial proton leak, we first compared the state 4 oxygen consumption rate of skeletal muscle mitochondria isolated from MDMA and PBS treated animals. We could show that the state 4 oxygen consumption rate by skeletal muscle mitochondria is increased only in MDMA treated animals, where the in vivo phosphorylation of the mitochondrial proteins are preserved ( Figure 5 ). Taking this fact together with the observation that MDMA does not affect UCP3 abundance (Figure 2 ), we can deduce that any , 1997; Krauss et al., 2005) .
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Having established that MDMA treatment increased state 4 oxygen consumption in skeletal muscle mitochondria, we set out to determine the contribution of UCP3 to the increased proton leak by comparing state 4 oxygen consumption rates in mitochondria from wild-type and UCP3 knock-out mice.
We were able to demonstrate that state 4 oxygen consumption rates were only increased in wild-type mice treated with MDMA under conditions where the in vivo phosphorylation state of the skeletal muscle mitochondria was preserved ( Figures 6A and 6D ). Furthermore, a comparison of mitochondria from wild-type and UCP3 knock-out mice clearly demonstrate that, all the increased state 4 oxygen consumption rate is due only to UCP3 as a result of MDMA treatment under conditions where we know UCP3 is phosphorylated ( Figure 6A and 6D) . No increase in state 4 oxygen consumption rate in mitochondria is observed under conditions where UCP3 is present but where we know UCP3 is not phosphorylated (6B and 6E). Our data also show no difference in maximal electron transport chain activity in a comparison of skeletal muscle mitochondria from wild-type and UCP3 knock-out mice ( Figures 6A and 6B) . Therefore, we conclude that the increase in state 4 oxygen consumption rate, after MDMA treatment, is due to increased proton leak through phosphorylated UCP3 .
Our observation that UCP3 needs to be covalently modified is consistent with data from in vitro activation studies from other laboratories that have demonstrated that UCP3 needs to be activated to catalyze a proton leak (Lee et al., 2009) . Certainly, addition of superoxide activates UCP3 in isolated skeletal muscle mitochondria resulting in increased and GDP-sensitive proton leak, probably as a result of generation of reactive polyunsaturated fatty acid oxidation products that covalently bind to UCP3
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22 (Echtay et al., 2002) . This position is endorsed by the observation that in vitro addition of highly reactive aldehydes, such as 4-hydroxy-2-nonenals to isolated mitochondria, increases proton leak of skeletal muscle mitochondria possibly through UCP's (Echtay et al., 2003) or possibly through a less specific mechanism (Shabalina et al., 2006) . The other interesting observationin our study, is the lack of purine nucleotide sensitivity of the skeletal muscle mitochondrial proton leak, catalyzed by in vivo activated/phosphorylated UCP3 (Figures 5 and 6 ). This contrasts with purine nucleotide sensitive nature of the in vitro covalent modification activation by 4-hydroxy-2-nonenals on UCP3 containing mitochondria reported by Echtay et al. (2003) , the purine nucleotide sensitive in vitro generated lipid hydroperoxide uncoupling activities reported for mitochondria by Lombardi et al. (2010) and the purine nucleotide sensitive proton leak reported for proteoliposomes containing expressed reconstituted UCP3 (Jabůrek et al., 1999; Echtay et al., 2001) . One explanation for the lack of purine nucleotide sensitivity to mitochondria containing activated/phosphorylated UCP3, may be due to the fact that our observations reflect the manifestation of the true in vivo mechanism of UCP3 activation or at least the in vivo mechanism of UCP3 activation as a result of administration of this particular pharmacological agent (MDMA) to animals. Future work will elucidate whether there is UCP3 activation through phosphorylation as a result of physiological stimuli and whether this too is purine nucleotide insensitive.
Interestingly, there is an independent observation of UCP3 insensitivity to purine nucleotide binding. Divakaruni et al. (2010) have shown that trypsinolysis of UCP3 in mitochondria, following addition of long-chain fatty acids to soluble protein is unprotected by GDP, unlike the situation in mitochondria that contain UCP1, suggesting that UCP3, unlike UCP1, does not bind GDP.
We should also point out that it is not uncommon, when comparing proton leaks, to measure proton leak kinetics i.e. state 4 oxygen consumption rate as a function of membrane potential driving the proton leak, and compare proton leak at a given membrane potential. In this study we chose to compare state 4 oxygen consumption rates (with reference to maximal electron transport chain activity) as means to compare proton leak. The reason for our strategy has to do with the accuracy of
23 measuring oxygen consumption rates in state 4. Due to its design, the instrument that we used to measure oxygen consumption, the Oroboros Oxygraph-2k respirometer, has minimal back diffusion of air/oxygen into the oxygen electrode chamber compared with Perspex oxygen electrode chambers (Gnaiger, 2001) . Further modification of a Perspex oxygen electrode chambers to accommodate electrodes to detect membrane potential obviously increases the rate of back diffusion of air/oxygen even further, resulting in an underestimation of state 4 oxygen consumption rates/proton leak rates by mitochondria. We wanted to achieve an accurate measure of state 4 oxygen consumption rates as possible and so used an Oxygraph-2k respirometer which as yet has no facility for measuring membrane potential. One can equate state 4 oxygen consumption rate with proton leak rate, as we know state 4 oxygen consumption is predominantly controlled by proton leak across the mitochondrial inner membrane (90%, Brand et al., 1988) . The remaining element controlling state 4 oxygen consumption is substrate supply and electron transport chain activity and the fact that we see no significant difference in maximal electron transport chain activity in a comparison of skeletal muscle from wild-type and UCP3 knock-out mice again reassures us that any difference in state 4 oxygen consumption rates are due to phosphorylated UCP3.
To conclude, by MDMA treatment of animals and by preserving the phosphorylation state of mitochondrial proteins we have discovered a novel in vivo mechanism by which UCP3 is activated to increase proton leak, namely in vivo covalent modification through phosphorylation of as yet unspecified serines and tyrosines on UCP3. It remains to be determined whether phosphorylation of UCP3 in skeletal muscle mitochondria is a primary physiological means of regulating UCP3 function or whether this type of activation is only a consequence of the pharmacological nature of MDMA. We
24
And finally, as mentioned earlier, the physiological significance of UCP3 activation has yet to be determined but UCP3 activation could be involved in cold-induced adaptive-thermogenesis. For instance Wijers et al. (2008) have demonstrated increased state 4 oxygen consumption in skeletal muscle mitochondria isolated from cold-acclimated humans. However, a recent study using cold acclimated wild-type and UCP1 knock-out mice states that "UCP3 is not innately uncoupling, that it cannot be induced to act as an uncoupler by either fatty acids or by endogenous reactive oxygen species, and that effects of GDP on respiration are not mediated by UCP3 study" (Shabalina et al., 2010) . Interestingly, Sun et al. (2003) have demonstrated that increased UCP3 protein levels in rat skeletal muscle following lipopolysaccharide/dexamethosone injection, possibly indicating a role for UCP3 involvement in thermogenesis in sepsis. Future work on UCP3 activation will focus on the aforementioned areas of research. from UCP 3 -/-and wild-type mice and liver mitochondria from wild-type mice were subjected to SDS-PAGE (12% resolving gel) and western blotted with a 1:500 dilution of affinity purified anti-UCP 3 peptide antibody (A) and a 1:1,000 dilution of commercial anti-PDH E1-α antibody (B). The ~ 33 kDa band and a ~44 kDa band denote the presence of UCP 3 and PDH E1-α respectively. 
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